AC
CO

Athos Capital’s Global Cord Blood Corporation CO Stock Holding History

Athos Capital’s Portfolio CO Stock Details CO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-59,862
Closed -$299K – 40
2019
Q4 		$299K Buy
59,862
+24,850
+71% +$119K 0.3% 32
2019
Q3 		$169K Buy
+35,012
New +$184K 0.17% 30

Other funds holding CO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
PI
PEAK6 Investments Chicago, Illinois $44.8B AUM 19.99% 1-Year Est. Return

Athos Capital's CO Position: Q1 2020 in Review

Athos Capital sold out of Global Cord Blood Corporation (CO) in Q1 2020, closing a stake of 59,862 shares — an estimated $299K sold.

Athos Capital first reported a position in CO in Q3 2019 and held it in 2 quarters. The position peaked at $299K in Q4 2019. 33 funds tracked by Wall St. Rank hold CO as of Q1 2020.

  • Athos Capital reported no remaining Global Cord Blood Corporation position as of Q1 2020 after selling out during the quarter.
  • Athos Capital sold 59,862 Global Cord Blood Corporation shares in Q1 2020, an estimated $299K.
  • Athos Capital first reported a position in Global Cord Blood Corporation in Q3 2019 and held it in 2 quarters.
  • Athos Capital's Global Cord Blood Corporation position peaked at $299K in Q4 2019.
  • 33 funds tracked by Wall St. Rank held Global Cord Blood Corporation as of Q1 2020.

Based on Athos Capital's 13F filing for Q1 2020, filed 12 May 2020.